The Experts below are selected from a list of 150 Experts worldwide ranked by ideXlab platform
Jacqueline M Miller - One of the best experts on this subject based on the ideXlab platform.
-
a tetravalent meningococcal serogroups a c w 135 and y tetanus toxoid conjugate vaccine is immunogenic and well tolerated when co administered with Twinrix in subjects aged 11 17 years an open randomised controlled trial
Vaccine, 2012Co-Authors: Lars Ostergaard, Yaela Baine, Svenarne Silfverdal, Johan Berglund, Carlerik Flodmark, Christina E West, Veronique Bianco, Jacqueline M MillerAbstract:The co-administration of the tetravalent meningococcal conjugate vaccine, MenACWY-TT, with a licensed hepatitis A and B vaccine, HepA/B (Twinrix(®)), was compared to their separate administration in this open, randomised, controlled study. Healthy subjects 11-17 years of age (n=611) were randomised (3:1:1) to receive both vaccines, MenACWY-TT alone or HepA/B alone. The co-administration of both vaccines was shown to be non-inferior to their individual administration. At seven months after the first vaccination, 99.4-100% of the subjects who received both vaccines co-administered showed seroprotection against all meningococcal serogroups and at least 99.1% of them were seropositive for hepatitis A and seroprotected against hepatitis B. This study suggests that MenACWY-TT vaccine could be co-administered with HepA/B without adversely impacting the immunogenicity, safety and reactogenicity of either of the vaccines.
Jim E Van Steenbergen - One of the best experts on this subject based on the ideXlab platform.
-
serological response to three alternative series of hepatitis b revaccination fendrix Twinrix and hbvaxpro 40 in healthy non responders a multicentre open label randomised controlled superiority trial
Lancet Infectious Diseases, 2020Co-Authors: Stijn Raven, Christian J P A Hoebe, Ann C T M Vossen, Leo G Visser, Jeannine L A Hautvast, Anna H Roukens, Jim E Van SteenbergenAbstract:Summary Background Serological non-response can be present after hepatitis B vaccination in healthy adults. We aimed to establish which of three revaccination regimens is most effective at inducing protective immunity Methods Healthy adults (aged 18–80 years) from 16 Dutch centres (13 public health services, two university hospitals, and one travel clinic) were included in this multicentre, parallel group, randomised, controlled, superiority trial. The inclusion criterion was vaccine non-response (hepatitis B surface antibody [anti-HBs] titre Findings The participants were recruited between Nov 1, 2012, and Sept 1, 2017. 480 participants were randomly assigned and included in intention-to-vaccinate analyses: 124 (26%) to control, 118 (25%) to Twinrix, 114 (24%) to HBVaxPro-40, and 124 (26%) to Fendrix. At month 3 the percentage of responders was 83 (67%) of 124 (95% CI 57·9–75·1 in the control group, 94 (80%) of the 118 (71·3–86·5) in the Twinrix group, 95 (83%) of 114 (75·2–89·7) in the HBVaxPro-40 group, and 108 (87%) of 124 (79·9–92·4) in the Fendrix group. Compared with the control group, the percentage of responders was superior for the HBVaxPro-40 group (adjusted difference 21·6% [95% CI 10·4–32·7], p=0·0204 [Bonferroni corrected p value]) and the Fendrix group (26·3% [15·4–37·3], p=0·0006), but not the Twinrix group (25·0% [13·0–37·0]; p=0·0846). One serious adverse event occurred (herpes zoster ophthalmicus) in the Fendrix group, which was not attributed to the vaccine. Interpretation Revaccinating healthy non-responders with Fendrix or HBVaxPro-40 resulted in significantly higher proportions of responders and therefore indication for these vaccines should be expanded to enable revaccination of non-responders. Funding National Institute for Public Health and the Environment.
Yaela Baine - One of the best experts on this subject based on the ideXlab platform.
-
a tetravalent meningococcal serogroups a c w 135 and y tetanus toxoid conjugate vaccine is immunogenic and well tolerated when co administered with Twinrix in subjects aged 11 17 years an open randomised controlled trial
Vaccine, 2012Co-Authors: Lars Ostergaard, Yaela Baine, Svenarne Silfverdal, Johan Berglund, Carlerik Flodmark, Christina E West, Veronique Bianco, Jacqueline M MillerAbstract:The co-administration of the tetravalent meningococcal conjugate vaccine, MenACWY-TT, with a licensed hepatitis A and B vaccine, HepA/B (Twinrix(®)), was compared to their separate administration in this open, randomised, controlled study. Healthy subjects 11-17 years of age (n=611) were randomised (3:1:1) to receive both vaccines, MenACWY-TT alone or HepA/B alone. The co-administration of both vaccines was shown to be non-inferior to their individual administration. At seven months after the first vaccination, 99.4-100% of the subjects who received both vaccines co-administered showed seroprotection against all meningococcal serogroups and at least 99.1% of them were seropositive for hepatitis A and seroprotected against hepatitis B. This study suggests that MenACWY-TT vaccine could be co-administered with HepA/B without adversely impacting the immunogenicity, safety and reactogenicity of either of the vaccines.
-
A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and Engerix-B) in adults.
Vaccine, 2001Co-Authors: Ronald W Joines, Mark M. Blatter, Betsy Abraham, Fang Xie, Norbert De Clercq, Yaela Baine, Keith S. Reisinger, A Kuhnen, Dennis L ParentiAbstract:In an open, randomized, multicenter, controlled clinical trial in the US, 773 adults were administered either a combination hepatitis vaccine (Twinrix: 720 EL.U inactivated hepatitis A antigen and 20 mcg recombinant hepatitis B surface antigen per milliliter) on a 0, 1, 6 month schedule or corresponding monovalent vaccines concurrently (Havrix, 1440 EL.U/ml of hepatitis A antigen at 0, 6 months and Engerix-B, 20 mcg of hepatitis B surface antigen at 0, 1, 6 months). Non-inferiority testing for the primary endpoint, severe soreness, and equivalence testing for the secondary endpoints, anti-HAV seroconversion and anti-HBs seroprotection, showed that safety and immunogenicity were comparable in the two groups.
Lars Ostergaard - One of the best experts on this subject based on the ideXlab platform.
-
a tetravalent meningococcal serogroups a c w 135 and y tetanus toxoid conjugate vaccine is immunogenic and well tolerated when co administered with Twinrix in subjects aged 11 17 years an open randomised controlled trial
Vaccine, 2012Co-Authors: Lars Ostergaard, Yaela Baine, Svenarne Silfverdal, Johan Berglund, Carlerik Flodmark, Christina E West, Veronique Bianco, Jacqueline M MillerAbstract:The co-administration of the tetravalent meningococcal conjugate vaccine, MenACWY-TT, with a licensed hepatitis A and B vaccine, HepA/B (Twinrix(®)), was compared to their separate administration in this open, randomised, controlled study. Healthy subjects 11-17 years of age (n=611) were randomised (3:1:1) to receive both vaccines, MenACWY-TT alone or HepA/B alone. The co-administration of both vaccines was shown to be non-inferior to their individual administration. At seven months after the first vaccination, 99.4-100% of the subjects who received both vaccines co-administered showed seroprotection against all meningococcal serogroups and at least 99.1% of them were seropositive for hepatitis A and seroprotected against hepatitis B. This study suggests that MenACWY-TT vaccine could be co-administered with HepA/B without adversely impacting the immunogenicity, safety and reactogenicity of either of the vaccines.
Stijn Raven - One of the best experts on this subject based on the ideXlab platform.
-
serological response to three alternative series of hepatitis b revaccination fendrix Twinrix and hbvaxpro 40 in healthy non responders a multicentre open label randomised controlled superiority trial
Lancet Infectious Diseases, 2020Co-Authors: Stijn Raven, Christian J P A Hoebe, Ann C T M Vossen, Leo G Visser, Jeannine L A Hautvast, Anna H Roukens, Jim E Van SteenbergenAbstract:Summary Background Serological non-response can be present after hepatitis B vaccination in healthy adults. We aimed to establish which of three revaccination regimens is most effective at inducing protective immunity Methods Healthy adults (aged 18–80 years) from 16 Dutch centres (13 public health services, two university hospitals, and one travel clinic) were included in this multicentre, parallel group, randomised, controlled, superiority trial. The inclusion criterion was vaccine non-response (hepatitis B surface antibody [anti-HBs] titre Findings The participants were recruited between Nov 1, 2012, and Sept 1, 2017. 480 participants were randomly assigned and included in intention-to-vaccinate analyses: 124 (26%) to control, 118 (25%) to Twinrix, 114 (24%) to HBVaxPro-40, and 124 (26%) to Fendrix. At month 3 the percentage of responders was 83 (67%) of 124 (95% CI 57·9–75·1 in the control group, 94 (80%) of the 118 (71·3–86·5) in the Twinrix group, 95 (83%) of 114 (75·2–89·7) in the HBVaxPro-40 group, and 108 (87%) of 124 (79·9–92·4) in the Fendrix group. Compared with the control group, the percentage of responders was superior for the HBVaxPro-40 group (adjusted difference 21·6% [95% CI 10·4–32·7], p=0·0204 [Bonferroni corrected p value]) and the Fendrix group (26·3% [15·4–37·3], p=0·0006), but not the Twinrix group (25·0% [13·0–37·0]; p=0·0846). One serious adverse event occurred (herpes zoster ophthalmicus) in the Fendrix group, which was not attributed to the vaccine. Interpretation Revaccinating healthy non-responders with Fendrix or HBVaxPro-40 resulted in significantly higher proportions of responders and therefore indication for these vaccines should be expanded to enable revaccination of non-responders. Funding National Institute for Public Health and the Environment.
